Communicable Diseases  >>  nivocasan (GS-9450)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
nivocasan (GS-9450) / Gilead
NCT00874796 / 2008-007456-96: Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection

Terminated
2b
307
US, Canada, Europe
GS-9450, Placebo
Gilead Sciences
HCV Infection
04/10
07/10
NCT00725803 / 2007-001601-16: Evaluation of the Safety, Tolerability, Pharmacokinetics, and Activity of GS-9450 in Subjects With Chronic HCV

Completed
2a
33
US, Europe
GS-9450, GS-9450 Placebo
Gilead Sciences
HCV Infection
10/08
03/09

Download Options